09:57 AM EDT, 04/04/2024 (MT Newswires) -- Merck ( MRK ) said Thursday it has begun a phase 3 clinical trial assessing MK-1084 plus Keytruda for the first-line treatment of patients suffering from metastatic non-small cell lung cancer.

The company said the trial's primary endpoints are progression-free and overall survival, while the key secondary endpoints comprise objective response rate and duration of response.

MK-1084, an investigational oral selective KRAS G12C inhibitor, is being developed in collaboration with Taiho Pharmaceutical and Astex Pharmaceuticals, Merck ( MRK ) said.

Price: 130.08, Change: +0.18, Percent Change: +0.14